CT scan

Canon Medical Launches Non-Obsolescence Program to help customers stay at forefront of care delivery

Retrieved on: 
Monday, November 28, 2022
Software, Magnetism, Heart, Healthcare disparity in Massachusetts, Canon Medical Systems Corporation, Health care, Safety, Trust, Patient, Radiology, Life, Marketing, Magnetic resonance imaging, Performance, Molecular imaging, Health, CT scan, Research, Quality of life, CT, CMSU, Medical imaging, Canon

With the rapid pace of innovation at Canon, customers can now maximize technology investments, stay current on meaningful innovations, and help extend the life of their equipment with this cost-effective, non-obsolescence program.

Key Points: 
  • With the rapid pace of innovation at Canon, customers can now maximize technology investments, stay current on meaningful innovations, and help extend the life of their equipment with this cost-effective, non-obsolescence program.
  • With this new offering, customers receive software and/or hardware enhancements, including cyber-security enhanced protection to their equipment as innovation becomes available.
  • This adds to a portfolio of initiatives such as Performance Pro training guarantee to help ensure that we are a trusted partner with our customers in the care they provide.
  • At Canon Medical, we work hand-in-hand with our partners our medical, academic and research communities.

GE Healthcare and ulrich medical announce an Agreement to Offer a Branded Multi-dose Contrast Media Injector in the U.S.

Retrieved on: 
Monday, November 28, 2022
Medical Supplies, Medical Devices, Health, Hospitals, Radiology, Pharmaceutical, Gesellschaft mit beschränkter Haftung, Cardiology, Active ingredient, Regulation of tobacco by the U.S. Food and Drug Administration, Agent handling, CGMP, Injection, Radiology, Iodine, Emergency department, Neurology, Record, API, Prevalence, Patient, USD, University of Washington Department of Bioengineering, Radiological Society of North America, Good manufacturing practice, Motion, Oncology, FDA, Diagnosis, Professor, Head, Cerebral angiography, Food, University, Conditional sentence, News, NYSE, Research, Radiopharmaceutical, Thomas Edison, Multimedia, RSNA, Patient safety, GE Healthcare, Insight, CT scan, Ecosystem, Congress, MDR, Medical imaging, Pharmaceutical industry, SQM

GE Healthcare has today announced an agreement with ulrich medical for a GE Healthcare branded contrast media injector in the U.S.

Key Points: 
  • GE Healthcare has today announced an agreement with ulrich medical for a GE Healthcare branded contrast media injector in the U.S.
  • The U.S. contrast media injector market is estimated to grow at 4.3 percent annuallyi between 2022-2030, attributed to its developed healthcare infrastructure and the prevalence of chronic diseases.
  • Today, the majority of contrast enhanced CT imaging involves radiology technicians filling a syringe with contrast media prior the injection procedure.
  • Marco Campione, Americas General Manager at GE Healthcare Pharmaceutical Diagnostics said: Radiology departments are focused on managing increasing demand and on conserving contrast media.

Fujifilm to Unveil New Medical Imaging Advances at the RSNA 2022 Conference

Retrieved on: 
Monday, November 21, 2022
Heart, Architecture, McCormick Place, Diagnosis, Tomosynthesis, Health, Laboratory, Gastroenterology, Anatomy, Mammography, AI, Digital radiography, Hospital, RSNA, Knowledge, Acquisition, Algorithm, Spine, Radiological Society of North America, ISS, Electricity, X-ray, MRI, Artificial intelligence, CEDM, Sale, OEM, Scoliosis, Google Images, CT scan, Radiology, DBT, FDR, Lithium, CT, Nursing, FDA, Enterprise imaging, Medical imaging, Renewable energy, Innovation, Fujifilm

When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patients body.

Key Points: 
  • When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patients body.
  • To learn more about Fujifilms presence at RSNA 2022 and to schedule an on-site meeting, please click here.
  • Fujifilms innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery.
  • The award-winning Synapse Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record.

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

Retrieved on: 
Monday, November 14, 2022
Trial of the century, Communication, Survival, Neck, Lymph, National Cancer Institute, Type 1, CT scan, Cancer, Mayo Clinic, Disease, Radiation, PDS, Toxicity, Immunotherapy, Treatment, Vaccine, Cervical cancer, Blood, Partnership, PET, University, Neoplasm, Research, Nature, Society, MD Anderson Cancer Center, Biotechnology, COVID-19, Merck & Co., Vulvar cancer, Warfarin necrosis, NCI, Merck, MRI, Human, CD8, Sharp, Nominal interest rate, Clinical professor, Therapy, FIGO, CRT, CPI, Gamma ray, III, Risk, Infection, Merck Sharp & Dohme Federal Credit Union, PDSB, Positron emission tomography, CR, Head, SITC, Pharmaceutical industry, Medical imaging, Patient

FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial was presented during a poster session on November 11 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022). These data expand upon results detailed in the abstract submitted to SITC 2022 that was released to the public on November 7.

Key Points: 
  • This includes 78% (7/9) of treated patients with advanced cervical cancer (FIGO stage III or IV).
  • 100% (9/9) of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage >60% at mid-point evaluation by MRI.
  • We look forward to the continued advancement of the IMMUNOCERV Phase 2 clinical trial and the opportunity to report updated data during 2023.
  • A third Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer is being led by The University of Texas MD Anderson Cancer Center.

UW–Madison To Perform the First U.S. Evaluation of GE Healthcare’s Photon Counting CT Technology with Deep Silicon Detectors

Retrieved on: 
Monday, November 21, 2022
Technology, Medical Devices, Hospitals, Software, Radiology, University, Health, Data Management, Education, Oncology, Sale, Medical physics, Health, Thomas Edison, Karolinska Institute, News, Public health, CE, Patient, NYSE, Radiology, CT scan, Noise, Research, Acquisition, Doctor of Philosophy, UW, GE Healthcare, Ecosystem, Insight, University, Molecular imaging, CT, Cardiology, Neurology, Biomedical engineering, Titanium carbide, UW Health University Hospital, Medical imaging, Pharmaceutical industry, Medical device, Photon, Medicine

Photon counting detectors push CT technology forward in two major ways: better spatial resolution and better contrast resolution, shares Tim Szczykutowicz, Ph.D., associate professor radiology at the school.

Key Points: 
  • Photon counting detectors push CT technology forward in two major ways: better spatial resolution and better contrast resolution, shares Tim Szczykutowicz, Ph.D., associate professor radiology at the school.
  • We are a part of the process of evaluating and developing this unique approach to photon counting based on Deep Silicon technology.
  • UWMadison will facilitate human subject research and produce technical feedback to test and advance GE Healthcares photon counting CT technology with Deep Silicon.
  • For more information on GE Healthcares unique approach to photon counting CT with Deep Silicon, visit gehealthcare.com .

FileShadow Adds the Power of Audio Annotation and Transcripts to Files

Retrieved on: 
Monday, November 21, 2022
Data Management, Technology, Photography, Audio, Video, Software, Internet, Cloud, DAS, Annotation, Google Drive, Yahoo!, Machine learning, Android, CT scan, OCR, Windows Virtual Desktop, Microsoft OneDrive, GPS, Office 365, IMAP, ICloud, Box, Web browser, Gmail, Windows Desktop Update, MacOS, Adobe Creative Cloud, Dropbox, Microsoft Exchange, PDF, IOS, Music, Online shopping, Medical imaging, Generic drug

FileShadow announced today that files in FileShadow can now be annotated with multiple audio recordings and automatically create transcripts of those recordings.

Key Points: 
  • FileShadow announced today that files in FileShadow can now be annotated with multiple audio recordings and automatically create transcripts of those recordings.
  • Users also have the option to send a link to the photos/documents/recordings so anyone can review the files via their web browser.
  • The uses for FileShadow Annotations are especially valuable in the genealogy, family history, medical, legal and creative industries, said Tyrone Pike, president and CEO of FileShadow.
  • Any group or industry that collaborates on documents, images, videos and other files can use Annotations to get work done faster.

GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity

Retrieved on: 
Thursday, November 17, 2022
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Medical Devices, Clinical Trials, SQM, Iohexol, Thomas Edison, API, News, Oncology, Multimedia, Active ingredient, NYSE, CT scan, Agent handling, Tissue, Radiopharmaceutical, Neurology, GE Healthcare, Growth, Iodine, Ecosystem, Insight, Diagnosis, Blood, Good manufacturing practice, Cardiology, Patient, Medical imaging, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20221117005624/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221117005624/en/
    Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second.
  • Recently, GE Healthcare announced a multi-year agreement with SQM , a Chile-based mining company, to secure increasing supply of iodine, the key ingredient in iodinated contrast media.
  • GE Healthcare is the worlds leading supplier of contrast media, used to support patient imaging procedures in 130+ countries globally.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

Small Animal Imaging (In-Vivo) Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Thursday, November 24, 2022
Photon, Single-photon emission computed tomography, Animal, Research report, Disease, Development, Vega, Pathology, Tissue, COVID-19, CT scan, Optical flow, Transducer, Life Technologies, Economy, GDP, Organization, Rigaku, CT, LI-COR Biosciences, Biomarker, PerkinElmer, Growth, General Electric, Acquisition, OECD, Promega, Bruker, PET, Miltenyi Biotec, Area studies, Agilent Technologies, Maternity leave and the Organisation for Economic Co-operation and Development, Milab, HIV disease progression rates, Medical imaging, Healthcare, New England Biolabs, SPECT

The small animal imaging (in-vivo) market is expected to grow to $3.38 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%.

Key Points: 
  • The small animal imaging (in-vivo) market is expected to grow to $3.38 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%.
  • The small animal imaging (in-vivo) market consists of sales of small animal imaging (in-vivo) products by entities (organizations, sole traders, and partnerships) that are used to observe, define, and quantify normal and pathologic processes in living animal organs and tissues non-invasively.
  • Technological advancement is a key trend gaining popularity in the small animal imaging (in-vivo) market.Major companies operating in the small animal imaging (in vivo) market are focused on technological advancement to strengthen their position.
  • The small animal imaging(in-vivo)market research report is one of a series of new reports that provides small animal imaging(in-vivo)market statistics, including small animal imaging(in-vivo)industry global market size, regional shares, competitors with a small animal imaging(in-vivo)market share, detailed small animal imaging(in-vivo)market segments, market trends and opportunities, and any further data you may need to thrive in the small animal imaging(in-vivo)industry.

Global Industrial Metrology Market to Reach $11.9 Billion by 2027

Retrieved on: 
Tuesday, November 8, 2022
Measuring instrument, Coordinate-measuring machine, Coordinate system, CT scan, Industry, Growth, Application, CAGR, 2021, CMM, Digitization, End-use certificate, ODS, Engineering, COVID-19, Equipment, Reverse engineering, North American Aerospace Defense Command, X-ray, Quality control, Automated optical inspection, Metrology, Renewable energy, Cereal, Flowers, Weapon, Machine tool, Petroleum, Surveying, Medical imaging, Dairy product, Generic drug, Lithium, Carbon fibers, Gasoline, Animal, Automotive industry

View original content:https://www.prnewswire.com/news-releases/global-industrial-metrology-mar...

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Industrial Metrology estimated at US$9 Billion in the year 2020, is projected to reach a revised size of US$11.9 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 7.6% CAGR
    The Industrial Metrology market in the U.S. is estimated at US$2.5 Billion in the year 2020.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 7.6% over the analysis period 2020 to 2027.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027.

PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

Retrieved on: 
Monday, November 7, 2022
National Cancer Institute, Neck, Population, Sharp, PDSB, Cervical cancer, Clinical trial, National, Partnership, University, SEC, SITC, Company, Merck, CT scan, GLOBE, Radiation, NCI, Vulvar cancer, Immunotherapy, Clinical professor, CEO, CR, CRT, Forward-looking statement, Vaccine, CPI, Society, Cancer, Blood, PET, Research, Biotechnology, Toxicity, Risk, Neoplasm, PDS, Merck & Co., COVID-19, Nature, Review, Head, Infection, Positron emission tomography, Goal, Mayo Clinic, Therapy, Lymph, Safety, Trial of the century, Nasdaq, MD Anderson Cancer Center, Merck Sharp & Dohme Federal Credit Union, Center, Communication, Pharmaceutical industry, Medical imaging, Patient

FLORHAM PARK, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced upcoming poster presentations of clinical data from two Phase 2 clinical trials of PDS0101 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022) being held November 8-12, 2022 in Boston. PDS0101 is PDS Biotech’s lead candidate being developed as a potential treatment for HPV-positive cancers.

Key Points: 
  • PDS0101 is PDS Biotechs lead candidate being developed as a potential treatment for HPV-positive cancers.
  • 8 of the 17 patients had completed a Day 170 post-treatment Positron Emission Tomography, Computed Tomography (PET CT) scan to assess the status of the cancer.
  • The 1-year overall survival is 100% (8/8) in patients treated with the combination of PDS0101 and CRT.
  • PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers.